Levosert (Levonorgestrel)

Levonorgestrel released from Levosert binds to progesterone receptors in the uterine lining. This action suppresses ovulation, thickens cervical mucus to block sperm, and creates endometrial changes that make implantation unlikely, resulting in effective contraception.

Levosert is supplied as a pre‑loaded 52 mg intrauterine system. The exact dosing regimen, including insertion timing and follow‑up schedule, is determined by the prescribing clinician based on individual patient factors and regulatory guidelines.

Levosert is intended for use in women who are not pregnant. If pregnancy occurs, the device should be removed. Limited data are available for breastfeeding; clinicians should weigh benefits against potential risks and discuss options with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levosert delivers a higher total amount of levonorgestrel (52 mg) than many copper IUDs, offering a hormone‑based mechanism that can reduce menstrual bleeding. Unlike copper devices, it does not rely on a foreign metal surface, which may be preferable for women with metal sensitivities.

Levosert should be stored at room temperature, below 25 °C, in its original sealed packaging. Protect the device from moisture, direct sunlight, and physical damage until it is inserted by a qualified healthcare professional.

Levosert is inserted into the uterine cavity by a trained clinician using a specialized inserter. The procedure is performed in a clinical setting under aseptic conditions, and the device remains in place for up to five years, after which it can be removed or replaced.

Serious risks include uterine perforation during insertion, device expulsion, and pelvic inflammatory disease. Rarely, allergic reactions to levonorgestrel or device components may occur. Patients should seek immediate medical attention if they experience severe abdominal pain, fever, or abnormal bleeding.

Levosert is contraindicated in women with active pelvic infection, known hypersensitivity to levonorgestrel, uterine anomalies that prevent proper placement, or current pregnancy. Women with a history of breast cancer or thromboembolic disorders should discuss alternative contraceptive methods with their healthcare provider.